SCHEMBL9932409

SCHEMBL9932409

CN(CCS(C)(=O)=O)c1cc(-c2nc3ccccc3n2C)c(Cl)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
USP2 O75604 2/20 0.41
RXFP1 Q9HBX9 2/20 0.40
ERAP1 Q9NZ08 2/20 0.40
KDM4E B2RXH2 7/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
TSHR P16473 3/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPT P10636 4/20 0.38
HSD17B10 Q99714 4/20 0.38
HTT P42858 3/20 0.38
LMNA P02545 3/20 0.38
TP53 P04637 2/20 0.38
PKM P14618 2/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9971209 0.87 MEN1 (0.39) MEN1KMT2ASMN1; SMN2USP2RXFP1
SCHEMBL9968296 0.86 MEN1 (0.45) MEN1KMT2ASMN1; SMN2RXFP1ERAP1
SCHEMBL9932202 0.85 MEN1 (0.44) MEN1KMT2ASMN1; SMN2RXFP1ERAP1
SCHEMBL9968510 0.85 MEN1 (0.44) MEN1KMT2ASMN1; SMN2USP2RXFP1
SCHEMBL9968293 0.84 MEN1 (0.44) MEN1KMT2ASMN1; SMN2RXFP1ERAP1
SCHEMBL9932761 0.83 MEN1 (0.43) MEN1KMT2ASMN1; SMN2USP2RXFP1
SCHEMBL9931547 0.82 MEN1 (0.41) MEN1KMT2ASMN1; SMN2USP2KDM4E
SCHEMBL9968292 0.81 MEN1 (0.43) MEN1KMT2ASMN1; SMN2USP2RXFP1
SCHEMBL9968512 0.80 MEN1 (0.42) MEN1KMT2ASMN1; SMN2USP2RXFP1
SCHEMBL9931924 0.80 MEN1 (0.41) MEN1KMT2ASMN1; SMN2RXFP1ERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2012-06-21 US disclosed
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2012-06-21 US disclosed
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2012-06-21 US disclosed
WO-2011027249-A2 BENZIMIDAZOLE DERIVATIVES PFIZER INC. (US) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157471-A1 BENZIMIDAZOLE DERIVATIVES SMO, RB1, GLI1 MEN1 1168/4885KMT2A 310/4885SMN1; SMN2 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.